Microbiome startup Seres Therapeutics expands Nestlé Health partnership

As microbiome startup Seres Therapeutics gets ready to bring its C. difficile treatment to the FDA, it has expanded its partnership with Nestlé Health, which is providing Seres with up to $500 million to commercialize the drug. $MCRB